Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Behavior therapy vs. Behavior therapy plus Mirabegron in men with OAB
NCT04420533Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Jun 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of mirabegron in overactive bladder syndrome (OAB), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Overactive Bladder Symptom Score at 12 weeks. Started Jun 2020; status: completed.
02
Drugs
mirabegron
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT04420533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04420533.